WallStSmart
DSGN

Design Therapeutics Inc

NASDAQ: DSGN · HEALTHCARE · BIOTECHNOLOGY

$15.79
-1.02% today

Updated 2026-06-05

Market cap
$745.11M
P/E ratio
P/S ratio
29,402.82x
EPS (TTM)
$-1.20
Dividend yield
52W range
$3 – $17
Volume
0.8M

Design Therapeutics Inc (DSGN) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-139000.00$-8.67M$-29.38M$-51.32M$-58.56M$-43.10M$-54.36M
Capital expenditures$76000.00$76000.00$1.54M$918000.00$256000.00$340000.00$193000.00
Depreciation$5000.00$5000.00$129000.00$406000.00$537000.00$-5.60M
Stock-based comp$0.00$450000.00$4.69M$10.93M$13.09M$13.07M$14.55M
Free cash flow$-215000.00$-8.74M$-30.91M$-52.23M$-58.82M$-43.45M$-54.55M
Investing cash flow$-33.56M$-33.56M$-53.64M$-220.99M$52.54M$43.95M
Financing cash flow$196000.00$44.53M$379.21M$235000.00$724000.00$513000.00
Dividends paid
Share repurchases
Debt repayment
Net change in cash$296.19M$-272.07M

Frequently asked questions

What is Design Therapeutics Inc's revenue?

Design Therapeutics Inc's trailing twelve-month revenue is $33000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does DSGN generate?

DSGN produced $-54.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is DSGN's balance sheet healthy?

DSGN holds $16.86M in cash and equivalents against — in long-term debt, on $212.50M of shareholder equity. That debt is best read against the cash flow the business throws off each year.